L1CAM High Expression Associates with Poor Prognosis in Glioma but Does Not Correlate with C11orf95-RELA Fusion

Table 1

Clinicopathological characteristics in relation to L1CAM expression.

	Total	L1CAM		L1CAM
		Negative		Positive
Total	565	456	(80.71%)	109	(19.29%)
Gender						0.400
Male	323	259	(80.19%)	64	(19.81%)
Female	242	197	(81.40%)	45	(18.60%)
Age						0.006
<=45	343	289	(84.26%)	54	(15.74%)
>45	222	167	(75.23%)	55	(24.77%)
Location						0.583
Supratentorial	517	413	(79.88%)	104	(20.12%)
Subtentorial	48	43	(89.58%)	5	(10.42%)
WHO grade						0.371
Low-grade (I and II)	197	161	(81.73%)	36	(18.27%)
High-grade (III and IV)	368	295	(80.16%)	73	(19.84%)
IDH						0.260
Mutated	240	196	(81.67%)	44	(18.33%)
Wildtype	325	260	(80.00%)	65	(20.00%)
ATRX						0.003
Mutated	239	215	(89.96%)	24	(10.04%)
Wildtype	326	241	(73.93%)	85	(26.07%)
P53						0.181
<=10%	245	193	(78.78%)	52	(21.22%)
>10%	320	263	(82.19%)	57	(17.81%)
Ki67						0.007
<=10%	194	168	(86.60%)	26	(13.40%)
>10%	371	288	(77.63%)	83	(22.37%)